Background
Inflammation can harm the heart during and after a procedure called percutaneous coronary intervention (PCI). Vitamin D can help reduce inflammation. This study looked at how two forms of Vitamin D—calcitriol and cholecalciferol—affect inflammation in patients undergoing PCI.
Study Overview
In this clinical trial, patients scheduled for PCI were divided into two groups: one received calcitriol and cholecalciferol, while the other did not. This took place from July 2021 to November 2022. The main focus was on a specific inflammatory marker called high-sensitive C-reactive protein (hs-CRP).
Results
A total of 180 patients participated, with an average age of 62. The patients who received calcitriol showed significantly lower levels of hs-CRP after 24 hours compared to those who did not receive it. However, there were no significant changes in other heart injury markers.
Conclusions
Giving calcitriol before PCI can lead to lower inflammation levels in the heart. More extensive studies are needed to understand the full impact of this treatment.
Measurable Outcomes
The key goal is to reduce hs-CRP levels in patients undergoing PCI through the use of calcitriol and cholecalciferol.
Next Steps
It’s important to start with a small pilot project to track how well these vitamin D treatments work in real clinical settings.
Contact Us
For more information on AI solutions in medical management, reach out to us:
Telegram: https://t.me/itinai
LinkedIn: https://www.linkedin.com/company/itinai/
